Mayo-TNBC cohort: Patient and disease characteristics at initial diagnosis. Table presents and confirms LAR clinical associations of increased age, AR protein expression, and enrichment of apocrine phenotype
| Variable . | LAR . | non-LAR . | . |
|---|---|---|---|
| . | n = 50 . | n = 219 . | P value . |
| Age at diagnosis | <0.001 | ||
| <50 years | 7 (14.0%) | 89 (40.6%) | |
| 50–6, 9 years | 26 (52.0%) | 102 (46.6%) | |
| ≥70 years | 17 (34.0%) | 28 (12.8%) | |
| Menopausal status | |||
| Premenopausal | 8 (16%) | 102 (46.6%) | <0.001 |
| Post-menopausal | 42 (84%) | 117 (53.4%) | |
| Histology | |||
| Ca w/ apocrine differentiation | 10 (20.0%) | 0 (0%) | <0.001 |
| Ca w/ medullary features | 7 (14.0%) | 49 (18.2%) | |
| Metaplastic carcinoma NST | 5 (10.0%) | 12 (4.5%) | |
| Invasive carcinoma NST | 28 (56.0%) | 158 (58.7%) | |
| Nottingham grade | |||
| 1–2 | 16 (32%) | 12 (6%) | <0.001 |
| 3 | 34 (68%) | 207 (95%) | |
| Ki67 | |||
| ≤15% | 17 (34.7%) | 39 (18.1%) | |
| >15% | 32 (65.3%) | 176 (81.9%) | |
| (not obtained) | (1) | (4) | 0.019 |
| AR IHC | |||
| Median | 70% | 0% | <0.001 |
| 25th–75th percentile | 22.5–92.5% | 0–0% | |
| (not obtained) | (10) | (46) | |
| AR | |||
| 0% | 7 (17.5%) | 135 (78.6%) | <0.001 |
| ≥1% | 33 (82.5%) | 37 (21.4%) | |
| (not obtained) | (10) | (46) | |
| Tumor size | |||
| ≤2.0 cm | 20 (40.0%) | 109 (49.8%) | |
| 2.1–5.0 cm | 26 (52.0%) | 96 (35.7%) | 0.434 |
| ≥5.1 cm | 4 (8.0%) | 14 (5.2%) |
| Variable . | LAR . | non-LAR . | . |
|---|---|---|---|
| . | n = 50 . | n = 219 . | P value . |
| Age at diagnosis | <0.001 | ||
| <50 years | 7 (14.0%) | 89 (40.6%) | |
| 50–6, 9 years | 26 (52.0%) | 102 (46.6%) | |
| ≥70 years | 17 (34.0%) | 28 (12.8%) | |
| Menopausal status | |||
| Premenopausal | 8 (16%) | 102 (46.6%) | <0.001 |
| Post-menopausal | 42 (84%) | 117 (53.4%) | |
| Histology | |||
| Ca w/ apocrine differentiation | 10 (20.0%) | 0 (0%) | <0.001 |
| Ca w/ medullary features | 7 (14.0%) | 49 (18.2%) | |
| Metaplastic carcinoma NST | 5 (10.0%) | 12 (4.5%) | |
| Invasive carcinoma NST | 28 (56.0%) | 158 (58.7%) | |
| Nottingham grade | |||
| 1–2 | 16 (32%) | 12 (6%) | <0.001 |
| 3 | 34 (68%) | 207 (95%) | |
| Ki67 | |||
| ≤15% | 17 (34.7%) | 39 (18.1%) | |
| >15% | 32 (65.3%) | 176 (81.9%) | |
| (not obtained) | (1) | (4) | 0.019 |
| AR IHC | |||
| Median | 70% | 0% | <0.001 |
| 25th–75th percentile | 22.5–92.5% | 0–0% | |
| (not obtained) | (10) | (46) | |
| AR | |||
| 0% | 7 (17.5%) | 135 (78.6%) | <0.001 |
| ≥1% | 33 (82.5%) | 37 (21.4%) | |
| (not obtained) | (10) | (46) | |
| Tumor size | |||
| ≤2.0 cm | 20 (40.0%) | 109 (49.8%) | |
| 2.1–5.0 cm | 26 (52.0%) | 96 (35.7%) | 0.434 |
| ≥5.1 cm | 4 (8.0%) | 14 (5.2%) |
Mayo-TNBC cohort: Patient and disease characteristics at initial diagnosis. Table presents and confirms LAR clinical associations of increased age, AR protein expression, and enrichment of apocrine phenotype
| Variable . | LAR . | non-LAR . | . |
|---|---|---|---|
| . | n = 50 . | n = 219 . | P value . |
| Age at diagnosis | <0.001 | ||
| <50 years | 7 (14.0%) | 89 (40.6%) | |
| 50–6, 9 years | 26 (52.0%) | 102 (46.6%) | |
| ≥70 years | 17 (34.0%) | 28 (12.8%) | |
| Menopausal status | |||
| Premenopausal | 8 (16%) | 102 (46.6%) | <0.001 |
| Post-menopausal | 42 (84%) | 117 (53.4%) | |
| Histology | |||
| Ca w/ apocrine differentiation | 10 (20.0%) | 0 (0%) | <0.001 |
| Ca w/ medullary features | 7 (14.0%) | 49 (18.2%) | |
| Metaplastic carcinoma NST | 5 (10.0%) | 12 (4.5%) | |
| Invasive carcinoma NST | 28 (56.0%) | 158 (58.7%) | |
| Nottingham grade | |||
| 1–2 | 16 (32%) | 12 (6%) | <0.001 |
| 3 | 34 (68%) | 207 (95%) | |
| Ki67 | |||
| ≤15% | 17 (34.7%) | 39 (18.1%) | |
| >15% | 32 (65.3%) | 176 (81.9%) | |
| (not obtained) | (1) | (4) | 0.019 |
| AR IHC | |||
| Median | 70% | 0% | <0.001 |
| 25th–75th percentile | 22.5–92.5% | 0–0% | |
| (not obtained) | (10) | (46) | |
| AR | |||
| 0% | 7 (17.5%) | 135 (78.6%) | <0.001 |
| ≥1% | 33 (82.5%) | 37 (21.4%) | |
| (not obtained) | (10) | (46) | |
| Tumor size | |||
| ≤2.0 cm | 20 (40.0%) | 109 (49.8%) | |
| 2.1–5.0 cm | 26 (52.0%) | 96 (35.7%) | 0.434 |
| ≥5.1 cm | 4 (8.0%) | 14 (5.2%) |
| Variable . | LAR . | non-LAR . | . |
|---|---|---|---|
| . | n = 50 . | n = 219 . | P value . |
| Age at diagnosis | <0.001 | ||
| <50 years | 7 (14.0%) | 89 (40.6%) | |
| 50–6, 9 years | 26 (52.0%) | 102 (46.6%) | |
| ≥70 years | 17 (34.0%) | 28 (12.8%) | |
| Menopausal status | |||
| Premenopausal | 8 (16%) | 102 (46.6%) | <0.001 |
| Post-menopausal | 42 (84%) | 117 (53.4%) | |
| Histology | |||
| Ca w/ apocrine differentiation | 10 (20.0%) | 0 (0%) | <0.001 |
| Ca w/ medullary features | 7 (14.0%) | 49 (18.2%) | |
| Metaplastic carcinoma NST | 5 (10.0%) | 12 (4.5%) | |
| Invasive carcinoma NST | 28 (56.0%) | 158 (58.7%) | |
| Nottingham grade | |||
| 1–2 | 16 (32%) | 12 (6%) | <0.001 |
| 3 | 34 (68%) | 207 (95%) | |
| Ki67 | |||
| ≤15% | 17 (34.7%) | 39 (18.1%) | |
| >15% | 32 (65.3%) | 176 (81.9%) | |
| (not obtained) | (1) | (4) | 0.019 |
| AR IHC | |||
| Median | 70% | 0% | <0.001 |
| 25th–75th percentile | 22.5–92.5% | 0–0% | |
| (not obtained) | (10) | (46) | |
| AR | |||
| 0% | 7 (17.5%) | 135 (78.6%) | <0.001 |
| ≥1% | 33 (82.5%) | 37 (21.4%) | |
| (not obtained) | (10) | (46) | |
| Tumor size | |||
| ≤2.0 cm | 20 (40.0%) | 109 (49.8%) | |
| 2.1–5.0 cm | 26 (52.0%) | 96 (35.7%) | 0.434 |
| ≥5.1 cm | 4 (8.0%) | 14 (5.2%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
